Pharmaceuticals company Indoco Remedies announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: During the fourth quarter of FY 2024-25, revenues of Indoco Remedies are at Rs 3,411 million, as against Rs 4,351 million, same quarter last year. EBIDTA for the quarter is at Rs 35 million, compared to Rs 574 million, same quarter last year. FY25 Financial Highlights: For the year, revenues are at Rs 14,948 million, as against Rs 17,620 million, same period last year. EBIDTA to net sales for the period is 8.6 % at Rs 1,280 million, compared to 14.6 % at Rs 2,580 million, same period last year. Profit After Tax are at Rs -87 million, compared to Rs 1,166 million, same period last year. Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “While this has been a challenging year for Indoco, there are several optimistic triggers which gives us confidence for a better future, both in the short as well as long term.” Result PDF
Conference Call with Indoco Remedies Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Indoco Remedies announced Q3FY25 results Revenue of Indoco Remedies is at Rs 3,649 million, as against Rs 4,484 million, Q3FY24. EBIDTA to net sales for the quarter is at Rs 201 million, compared to Rs 653 million, Q3FY24. Aditi Panandikar, Managing Director, Indoco Remedies, said: “Domestic Formulation Business continued to contribute in revenue growth, while the Export Formulation Business has been impacted by supply constraints from our sites that underwent planned shutdowns for enhancement of capacities and productivity.” Result PDF